The company sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. Amarin has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA.
Cyborg Score Rationale
Amarin is an established commercial-stage pharmaceutical company with a FDA-approved flagship product (VASCEPA) generating revenue. The narrow focus on cardiovascular therapeutics and reliance on a single product present concentration risk, but successful commercialization demonstrates execution capability and market traction.
Top Insights
VASCEPA is the company's core revenue driver; commercial success depends on prescription volume growth and market penetration in cardiovascular disease management
International expansion underway in Canada, Lebanon, and UAE; regulatory approvals sought in China, Europe, and other Middle Eastern markets
Strategic partnership with Mochida Pharmaceutical expands development pipeline and geographic reach for EPA-based therapies
Narrow product portfolio creates vulnerability to regulatory changes, competitive pressures, or reimbursement challenges in the hypertriglyceridemia indication
Named Competitors
Repatha — Prescription PCSK9 inhibitor for cardiovascular disease and lipid management
Praluent — PCSK9 inhibitor for lowering LDL cholesterol in cardiovascular patients
Nexletol — Bempedoic acid for lowering LDL cholesterol and triglycerides
Inclisiran — PCSK9 inhibitor for cardiovascular disease and lipid management
Open the full interactive Amarin Corporation plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.